A
Andrea Necchi
Researcher at Vita-Salute San Raffaele University
Publications - 101
Citations - 2384
Andrea Necchi is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Bladder cancer & Pembrolizumab. The author has an hindex of 13, co-authored 100 publications receiving 1206 citations. Previous affiliations of Andrea Necchi include University of Rostock & University of Ulsan.
Papers
More filters
Journal ArticleDOI
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot,Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert Huddart,Elizabeth A. Burgess,Mark D. Fleming,A. Rezazadeh,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Yousef Zakharia,B. Zhong,K. Stuyckens,A. Santiago-Walker,P. De Porre,A. O'Hagan,A. Avadhani,Arlene O. Siefker-Radtke +20 more
TL;DR: The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations.
Journal ArticleDOI
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study
Andrea Necchi,Andrea Anichini,Daniele Raggi,Alberto Briganti,Simona Massa,Roberta Lucianò,Maurizio Colecchia,Patrizia Giannatempo,Roberta Mortarini,Marco Bianchi,Elena Farè,Francesco Monopoli,Renzo Colombo,Andrea Gallina,Andrea Salonia,Antonella Messina,Siraj M. Ali,Russell Madison,Jeffrey S. Ross,Jon Chung,Roberto Salvioni,Luigi Mariani,Francesco Montorsi +22 more
TL;DR: It is indicated that pembrolizumab could be a worthwhile neoadjuvant therapy for the treatment of MIBC when limited to patients with PD-L1-positive or high-TMB tumors.
Journal ArticleDOI
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
J. Alfred Witjes,Marek Babjuk,Joaquim Bellmunt,H. Maxim Bruins,Theo M. de Reijke,Maria De Santis,Silke Gillessen,Nicholas D. James,Steven MacLennan,Juan Palou,Thomas Powles,Maria J. Ribal,Shahrokh F. Shariat,Theo H. van der Kwast,Evanguelos Xylinas,Neeraj Agarwal,Tom J.H. Arends,Aristotle Bamias,Alison Birtle,Peter C. Black,Bernard H. Bochner,Michel Bolla,Joost L. Boormans,Alberto Bossi,Alberto Briganti,Iris Brummelhuis,Max Bürger,Daniel Castellano,Richard Cathomas,Arturo Chiti,Ananya Choudhury,Eva Comperat,Simon J. Crabb,Stéphane Culine,Berardino De Bari,Willem de Blok,Pieter De Visschere,Karel Decaestecker,Konstantinos Dimitropoulos,J. Domínguez-Escrig,Stefano Fanti,Valérie Fonteyne,Mark Frydenberg,Jurgen J. Fütterer,Georgios Gakis,Bogdan Geavlete,Paolo Gontero,Bernhard Grubmüller,Shaista Hafeez,Donna E. Hansel,Arndt Hartmann,Dickon Hayne,Ann Henry,Virginia Hernández,Harry W. Herr,Ken Herrmann,Peter Hoskin,Jorge Huguet,Barbara Alicja Jereczek-Fossa,Robert Jones,Ashish M. Kamat,Vincent Khoo,Anne E. Kiltie,Susanne Krege,Sylvain Ladoire,Pedro C. Lara,Annemarie Leliveld,Estefania Linares-Espinós,Vibeke Løgager,Anja Lorch,Yohann Loriot,Richard P. Meijer,M. Carmen Mir,Marco Moschini,Hugh Mostafid,Arndt-Christian Müller,Christoph R. Müller,James N'Dow,Andrea Necchi,Yann Neuzillet,Jorg R. Oddens,Jan Oldenburg,Susanne Osanto,Wim J.G. Oyen,Luís Pacheco-Figueiredo,Helle Pappot,Manish I. Patel,Bradley R. Pieters,Karin Plass,Mesut Remzi,Margitta Retz,Jonathan Richenberg,Michael Rink,Florian Roghmann,Jonathan E. Rosenberg,Morgan Rouprêt,Olivier Rouvière,Carl Salembier,Antti Salminen,Paul Sargos,Shomik Sengupta,Amir Sherif,Robert Jan Smeenk,Anita Smits,Arnulf Stenzl,George N. Thalmann,Bertrand Tombal,Baris Turkbey,Susanne Vahr Lauridsen,Riccardo Valdagni,Antoine G. van der Heijden,Hein Van Poppel,Mihai Dorin Vartolomei,Erik Veskimäe,Antoni Vilaseca,Franklin A. Vives Rivera,Thomas Wiegel,Peter Wiklund,Andrew K. Williams,Richard Zigeuner,Alan Horwich +120 more
TL;DR: These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the managementof oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease.
Journal ArticleDOI
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y. Yu,Evan Y. Yu,Daniel P. Petrylak,Peter H. O'Donnell,Jae-Lyun Lee,Jae-Lyun Lee,Michiel S. van der Heijden,Yohann Loriot,Mark N. Stein,Andrea Necchi,Takahiro Kojima,Michael R. Harrison,Se Hoon Park,David I. Quinn,Elisabeth I. Heath,Jonathan E. Rosenberg,Joyce Steinberg,Shang-Ying Liang,Janet Trowbridge,Mary Campbell,Bradley Alexander McGregor,Arjun Vasant Balar +21 more
TL;DR: Enfortumab vedotin is an antibody-drug conjugate directed at Nectin-4, a protein highly expressed in urothelial carcinoma as discussed by the authors.
Journal ArticleDOI
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
David J. Vaughn,Joaquim Bellmunt,Yves Fradet,Jae-Lyun Lee,Lawrence Fong,Nicholas J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Yabing Mai,Haojie Li,Rodolfo F. Perini,Dean F. Bajorin,Ronald de Wit +19 more
TL;DR: The results of health-related quality-of-life (HRQoL) analyses from the KEYNOTE-045 trial support pembrolizumab as standard of care for patients with platinum-refractory advanced urothelial cancer.